|
Speeches
AUSTRALIAN
NATIONAL UNIVERSITY
CONFERENCE
ON CONSTRUCTING LAW & DISABILITY
4
DECEMBER 2000
DISABILITY
AND THE HUMAN GENOME
TO
IGNORE IS TO DECIDE
The
Hon Justice Michael Kirby AC CMG
Quito is a remarkable city. It has been included
in the World Heritage List for its extraordinary natural features
and historical significance. Before the Spanish arrived
in South America, the town and its indigenous Kingdom fell
to the Incas. In time, it was conquered by the Spaniards.
In 1532 they used it as their base to subdue Peru. Under
the Spanish, many beautiful churches were built and residences
began to cover the mountains of Quito that represent the foothills
of the Andes. Not far from Quito, the glistening top
of Cotapaxi can be seen through the morning mist.
The Spanish were eventually driven from the Republic
of Gran Colombia in 1809. In 1830, Ecuador proclaimed
its own constitution and became a separate nation. Quito
is its capital. To Quito, in November 2000, came participants
from all over the world. Their purpose was to take part
in the first meeting of the International Bioethics Committee
of UNESCO (IBC) to be held in South America.
I took part in this meeting. Most of its sessions
were concerned with subjects relevant to the implications
for morality, law and society of the advances in genetic science.
This was the first meeting of the IBC since the announcement,
in June 2000, of the completion of the first provisional draft
of the human genome. Although the mandate of the IBC
is wider than human bioethics and the human genome, it was
natural that the meeting in Quito should be mostly concerned
with those topics.
Amongst the issues which the IBC members discussed
were public education in bioethics; intellectual property
protection of biotechnology; and the implications of embryonic
stem cell research and development.
Education issues inspired an important session.
Unless the public understands the developments of genomic
science, it can scarcely be criticised for failing to perceive,
and to act upon, the implications which such science presents
for the law and society. One of the interesting topics
addressed during this session was a world-wide proposal for
enhancing training in ethical questions at university medical
faculties. Nowadays, even more than in the past, medical
practitioners have to deal with acutely difficult ethical
problems, many of them with legal ramifications. It
is astonishing that some medical graduates can reach that
status and responsibility without training in the ethical
quandaries that they will have to resolve, consistently with
law, during their lifetime in medical practice. The
IBC expressed its support for the efforts to improve public
education in bioethical questions, including by the promotion
of special courses in medical schools. It may be hoped
that this idea will be followed up in Australia and many other
lands.
The subject of intellectual property protection is
amongst the most important presented by advances in knowledge
about the genome. Although the Universal Declaration
of the Human Genome and Human Rights, adopted by the IBC
and accepted by the General Conference of UNESCO and the General
Assembly of the United Nations, speaks of the human genome,
in its natural state, as part of the "common heritage
of mankind" intellectual property law is invoked to provide
temporary rights of exclusive use or licence to patent holders,
by reference to the genome. Pharmaceutical corporations
and others justify these rights on the basis that, unless
guaranteed such protection for new "inventions",
the huge investments that are necessary to translate basic
scientific knowledge into therapies and other treatments,
of benefit to humanity, will not occur. In my experience,
now over ten years, it can be said with assurance that this
is a topic that causes very strong feelings in any international
meeting at which it is raised. Participants from developed
countries tend to emphasise the importance of applying intellectual
property regimes, both international and domestic, to genomic
technologies so as to maximise the benefits derived from them.
Participants from developing countries express concern that
such laws will be used to deprive them of a share in the medical
advances that will flow from unveiling the genome. In
short, they express concern that intellectual property law
will be used to cut people in developing countries off from
effective access to knowledge about human genetics and the
application to which that knowledge is put.
No resolution of these questions was reached, or indeed
expected, at the Quito meeting. But the participants
were heartened by the advice given to the meeting by the Secretary-General
of the IBC (Dr Georges Kutukdjian) concerning the interest
taken in this topic by the new Director-General of UNESCO,
(Mr Koïchiro Matsuura). The Director-General has summoned
an international meeting in Paris on 1-2 February 2001.
It will be attended by the major players in the debate about
intellectual property protection. I will attend this
meeting myself.
Probably the hottest topic on the agenda of the IBC
concerned the use of embryonic stem cells. This topic
is controversial because of different views adopted by different
religious and other teachings, concerning the morality of
experimentation involving human embryonic cells. Within
these cells, the so-called "stem cells" - which
represent the earliest forms of human living material - are
believed to have great potential utility for medical research
and therapies. The prospect was described recently in
the Washington Post, in terms that are easily understood:
"Pick a disease - Alzheimers, cancer,
diabetes. You want The Cure. Scientists take some
of your skin cells and create your clone in a Petrie dish.
In about a week, the cloned embryo is the size of a period
at the end of a sentence. Theoretically this small cluster
of cells has the potential to become a human being.
But your clone is not destined to born. ... Instead
the cloned embryo will become a kind of natural factory in
which your body's generic cells are grown and shaped into
cures - brain cells for Alzheimer's, bone marrow cells for
cancer, pancreatic cells for diabetes".
Many observers, mostly scientists, and a good number
of those participating in the IBC meeting in Quito, shared
an enthusiasm for the potential of this scientific development.
To them, it promises the relief of unnecessary pain and premature
death caused either by genetic predisposition to disability
(such as Alzheimer's Disease, Parkinson's Disease or Huntington's
Disease) or traumatic injury occasioned, perhaps, by genetic
predisposition (such as the death of heart muscle caused by
myocardial infarction). The prospect of utilising human
stem cells, cloned to the recipient, calling upon their puripotent
(or even totipotent) capacity to replicate the cells of the
disabled person, fills many scientists, and not a few lay
people, with wonderment and anticipation at the awesome products
of the human mind and modern technology.
However, some of the participants in the Quito meeting
shared concerns about the use of embryonic stem cells - even
those as tiny as the cells described above. Did this
not mean utilising the cells of an embryo which was the first
product of a human conception, and thus, potentially (given
conducive circumstances) capable of developing into a full
human being?
In the debates on this topic, I witnessed one of the
major quandaries for the IBC, indeed for deriving solutions
to the issues of bioethics in a world of diverse religions
and disparate philosophical opinions.
Amongst some Roman Catholic and Orthodox Christian
theologians, the use of embryo cells in this way is totally
unacceptable. This follows from views concerning the
meaning of conception of human life. If the view is
taken that conception is the first moment of human existence,
it is easy to proceed to a conclusion that the law should
protect such life and forbid experimentation with its cells.
The debate on this topic has roots in the earlier controversies
about the procedures involved in in vitro fertilisation
(IVF). That technique uses "surplus" embryos
created specifically, in larger number than would eventually
be used to develop human persons, so as to increase the chances
of conception in utero. Views have been expressed
by the Roman Catholic Church that research on the use of embryonic
stem cells is contrary to basic moral precepts.
According to a paper tabled at the IBC, written by
Professor Michel Revel of the Weizman Institute in Israel,
Jewish Biblical and Talmudic law considers that human status
is only acquired progressively during foetal development and
not at the moment of conception.
Genetic materials, outside the uterus, therefore have no legal
status in Jewish law. They are not even part of a human
being until they are implanted within the womb. Even
then, during the first 40 days, their status is not that of
a formed human being and thus they are not entitled to protection
according to Jewish notions of morality or civil law.
Professor Revel's paper points out that Islam, similarly,
postpones the moment at which personhood can be seen to exist
in a foetus - which is a much developed embryo. The
law (Shari'a) teaches that ensoulment of the human foetus
does not take place until three periods of 40 days, ie at
120 days, or the turn of the first trimester. Although
the embryo is alive in the womb before it receives a soul,
protection of the embryo before ensoulment is not subject
to the same strict conditions.
There are Roman Catholic views that question the Church's
orthodox opinion about the human individual beginning at the
moment of conception.
According to such views, human existence does not begin
at fertilisation of the ovum but when the "primitive
streak" first manifests itself in the embryonic development,
at about 14 or 15 days after conception. If that view
were ultimately accepted, experimentation with early stem
cells, within that time interval, presents no particular difficulty
for religious beliefs or morality. Prior to the formation
of the "primitive streak" - the first outline of
a potential spine - the human embryonic cells are not truly
a human life in potential. They are is just part of
nature's profligate creation of life and thus, upon this view,
available for experimental research and therapeutic use, so
long as the purposes of that research and use is ultimately
for the alleviation of disability and prevention of premature
or unnecessary death.
The point I make concerning these controversies, which
consumed much time at the Quito meeting, is this. Developments
of the human genome affect the whole human family. In
a sense, they relate to nothing less than the future of our
species. They are therefore of legitimate concern to
all human beings. Securing a common approach to the
regulation of experimentation and therapy is therefore properly
a matter of global attention. But securing agreement
about what such regulation should say, if anything, is extremely
difficult. This is because of the differences of view
that exist in and between the major religions of the world.
And in competition with the religious opinions are the views
of major philosophical beliefs, such as Buddhism and of humanists
who reject a starting point in religious dogma. Many
adherents to humanism regard as absurd the notion that an
embryo, no bigger than a fullstop on the printed page, part
of nature's massive excess production of living cells, external
to a womb with no realistic potential to develop into a human
being, must be given all the protections of a human life -
whether on the basis of morality or law. For people
of this conviction, nothing at all should be done to impede
the advance of science and technology and the potential use
of stem cells for further research and therapeutic utilisation.
The IBC was unable to reach final agreement on the
issue of embryonic stem cell use. It is hoped that a
tentative position will be reached by the IBC working party
in February 2001. It is important to recognise that,
in this matter, not to make a decision is effectively to make
one. If the international community, and domestic law,
say nothing on experimentation with embryonic stem cells,
the result will be that such experimentation will certainly
proceed. And even if the law of one state forbids such
experimentation, the likelihood is that it will proceed in
other states. It will be very difficult to contain such
research (with its huge potential, including economic potential)
in one country alone or even by the laws of many countries.
This is why international reflection on the topic is so important.
Time was not wasted in Quito.
Pursuant to the Universal Declaration on the Human
Genome and Human Rights, a number of representatives of
patients' associations were invited to Quito. They addressed
a meeting of the IBC which, on this topic, was held in plenary
session and in public. The representatives of the patients'
associations spoke of the genetic revolution from the point
of view of those who themselves suffer, for example, from
Parkinson's Disease or who are members of voluntary bodies
formed to represent, and protect the rights of, family members
suffering from genetic conditions, such as Huntington's Disease.
The explanation of the viewpoints of the patients'
associations was extremely moving. As I was later to
explain to the IBC, they struck a chord with me because of
my own experience as a homosexual man. Although I do
not regard my sexuality as a "disability", there
is no doubt that some people would do so.
Indeed, the hate mail I have received since publicly disclosing
my sexuality, indicates that this view is not at all uncommon,
even in relatively enlightened Australia. I therefore
understand the feelings of people with genetic conditions
and family members of such people, when the issue that is
crucial to this debate is raised. That issue, put simply,
is elimination.
In many countries, including Australia, the foetus,
in certain cases, is virtually automatically checked for evidence
of the assistance of genetic conditions such as profound mental
retardation. In such cases the parents are given counselling
which, in many instances, leads to a termination of the pregnancy.
Of course, termination is not obligatory. But such decisions
are regularly made. Apparently, they are condoned
by law and certainly by medical practice.
The issues which are presented by the advance of the
human genome project include the question of how far down
the road of elimination our societies will go. Is it
conceivable, either in the short term or some time in the
coming century, that a foetus will be aborted for no reason
other that it manifests the gene for Huntington's Disease?
Or for sickle cell anaemia? Or for schizophrenia?
Or for early onset baldness? Or (if it ultimately be
shown to be a genetically influenced condition) homosexuality?
By what principle is elimination to be allowed or forbidden
in law? Once again, it is important to note that the
absence of law will, effectively, turn such questions over
to be determined, in effect, by parents and the doctors who
advise them. Social forces, public opinion and even
economic considerations may then influence the determination
of where the line is drawn. We may think it intolerable
to eliminate a foetus for reasons of potential baldness.
But if parents desire to avoid a family tendency towards early
baldness, should they be denied the choice of an embryo without
that gene, in preference to one with it? Is there a
risk that a schedule of undesired genetic conditions may be
established, affording a comprehensive screening process through
which embryos in vitro or foetuses in utero
are tested to assure parents of the child of their dreams?
If such practices are not forbidden by law, it is likely
that, within the market, somewhere, some such developments
will occur. Anyone in doubt should reflect upon the
significant ill-balance between male and female newborns in
India and China. If this can occur with reference to
one genetic condition - sex - and often without sophisticated
medical technology it will, before long, be available by reference
to a multitude of other conditions deemed by particular parents
to be unwanted in their child. Where would this have
left the embryo that, born, produced Beethoven with his congenital
deafness? Milton with his blindness? Mahler with
his heart defect? In the past, the variety of humanity
has been a feature of human freedom; and also, sometimes,
a very practical protection against genetic diseases and epidemics.
The advance of genomic science brings, with every year,
new paradoxes that have to be resolved. A recent report
in English newspapers disclosed a fresh quandary; but it is
likely to present itself in Australia before long. The
science editor of a London daily reported that disabled parents
in England are now seeking the right to choose to have disabled
children, produced with the aid of new genetic screening tests
that are becoming more widely available.
According to the report, government advisers in Britain are
considering allowing deaf parents to decide to have deaf children
on the basis that it might be in the child's interests to
be born with the same disability as their parents. The
issue was raised by the British Human Fertilisation and Embryology
Authority. Reportedly it is considering the ethical
implications of the technique that can distinguish between
healthy and abnormal "embryos in the test tube".
Critics of the proposals were said to be arguing that
wide scale introduction of Preimplantation Genetic Diagnosis
(PGD) would raise the prospect of disadvantaged babies being
conceived and delivered deliberately, because specifically
chosen by parents with similar disabilities. Supporters
of the proposal have argued that certain disabilities, such
as deafness, are so mild that it could, in the long term,
be in the best interests of a child to have the same disability
as its parents so as to experience a similar life and outlook.
Professor Alan Templeton, Chairman of the Working Group
on PGD at the British Authority, reportedly stated that the
issue had been raised by patient bodies, including those representing
certain kinds of dwarfism. Patients in such bodies have
expressed the opinion that they should be allowed to choose
children more like themselves. The issue has divided
opinions amongst obstetricians and gynaecologists who advise
the Authority's committee. Some, who have considered
the matter, regard the notion of choosing deliberately an
embryo manifesting deafness or dwarfism genes as pandering
to the desires of parents rather than reflecting the
best interests of a child. Ordinarily decisions
affecting children must conform to the best interests rule.
But where does the best interest of a child lie in a family
where a disability exists in one or both parents? A
spokesman for the National Deaf Children's Society explained
concern that he felt about genetic testing:
"Naturally I'm
concerned at the possibility of it being used for 'cleansing'
of deaf children but it can be a great tool in early diagnosis
for hearing parents in order to prepare all the support
for their deaf children".
The recent developments in technology, including cochlea
implants, have revolutionised the assistance that can be given
to those deaf persons who desire to improve their hearing
mechanically.
But is the logic of such technology the ultimate removal from
the human family of deaf persons, diagnosed by genetic testing?
Is this a legitimate advance of science and the removal of
a disability that is a burden on the person affected, his
or her family and perhaps the state? Or is it an attempt
to manipulate science to perform a form of disability cleansing?
Does one's answer to these questions reflect a stereotyped
conception of the perfect child, which itself can be manipulated
by media and public opinion? Given that most parents
are heterosexual, few might naturally feel a strong desire
to have a child who was homosexual. Yet, in the past,
a proportion of every society has been homosexual. If
the criterion is identity with parents, where does the application
of that criterion stop? In the randomness of nature
there were disabilities, it is true. But there was also
variety and difference that contributed to the world of dazzling
variety, as we know it.
These are some of the issues which the human genome
project presents to the global community. Obviously,
they are issues of considerable importance to society and
the law. They have relevance to disability and the law.
They concern people living with disabilities, their families
and representative organisations.
At least the IBC of UNESCO is listening to the voice
of patient organisations. An expression of solidarity
with patients' associations was adopted at the meeting in
Quito. It was not very specific. It did not go
into the details of the measure of the solidarity and the
implications of it for the issues, some of which I have outlined.
It will be important in the future work of the IBC that patients'
organisations should be regularly heard. And when they
are heard, the question will have to be answered. When
is human variety a disability? Some genetic conditions are
distinctly bad news. There is no inherent beauty in
prolonged pain and human suffering, genetic or otherwise.
There is no glory in the premature termination of sentient
human life and sensibility. Relieving pain and suffering
and promoting life and sensibility are generally good things.
They are worthy objectives of morality and of law. But
sometimes disability depends upon the eye or ear or mind of
the beholder. Getting agreement on these issues is difficult
locally, more difficult nationally and almost impossible internationally.
Yet the issue is undoubtedly an international one. UNESCO's
IBC does not have the option to ignore the puzzles of genomics.
None of us has that option. To ignore is to decide.
|